An update from Intra-Cellular Therapies (ITCI) is now available.
Sanjeev Narula has been appointed as the new Executive Vice President, Chief Financial Officer and Treasurer of a prominent company, effective August 12, 2024. With over 30 years of experience, including a significant tenure in the biopharmaceutical industry, Narula brings a wealth of expertise to his new role. His compensation includes a $615,000 base salary, potential bonuses, equity grants, and a sign-on bonus, along with standard executive benefits and severance provisions. His predecessor, Lawrence J. Hineline, will retire but continue as a consultant to ensure a smooth transition.
See more data about ITCI stock on TipRanks’ Stock Analysis page.
